62.62
0.98%
-0.62
ANI Pharmaceuticals Inc stock is currently priced at $62.62, with a 24-hour trading volume of 88,445.
It has seen a -0.98% decreased in the last 24 hours and a -5.16% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $63.46 pivot point. If it approaches the $62.35 support level, significant changes may occur.
Previous Close:
$63.24
Open:
$62.73
24h Volume:
88,445
Market Cap:
$1.31B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-130.46
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-6.17%
1M Performance:
-5.16%
6M Performance:
+18.37%
1Y Performance:
+26.07%
ANI Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
ANI Pharmaceuticals Inc
Sector
Phone
218-634-3500
Address
210 Main Street West, Baudette, MN
ANI Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
Mar-01-23 | Initiated | Guggenheim | Buy |
Sep-07-22 | Initiated | H.C. Wainwright | Buy |
Nov-02-21 | Initiated | Truist | Buy |
May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-19 | Initiated | Guggenheim | Buy |
May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
Jul-31-17 | Initiated | Canaccord Genuity | Buy |
Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-23-16 | Initiated | Raymond James | Strong Buy |
May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
Nov-13-15 | Initiated | Standpoint Research | Buy |
Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
Aug-05-15 | Reiterated | Oppenheimer | Outperform |
Aug-04-15 | Reiterated | ROTH Capital | Neutral |
Jul-31-15 | Reiterated | Oppenheimer | Outperform |
Jul-15-15 | Reiterated | ROTH Capital | Neutral |
Jun-23-15 | Reiterated | Oppenheimer | Outperform |
May-18-15 | Reiterated | ROTH Capital | Neutral |
May-06-15 | Reiterated | Oppenheimer | Outperform |
Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
Feb-26-15 | Reiterated | ROTH Capital | Buy |
Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
ANI Pharmaceuticals Inc Stock (ANIP) Latest News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares - MarketBeat
MarketBeat
Ani Pharmaceuticals executive sells shares worth over $15k - Investing.com India
Investing.com India
Ani Pharmaceuticals executive sells shares worth over $15k By Investing.com - Investing.com
Investing.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update - MarketBeat
MarketBeat
C M Bidwell & Associates Ltd. Sells 2081 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Defense World
Clear Street Markets LLC Buys Shares of 2531 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Defense World
ANI Pharmaceuticals Inc Stock (ANIP) Financials Data
ANI Pharmaceuticals Inc (ANIP) Revenue 2024
ANIP reported a revenue (TTM) of $486.82 million for the quarter ending December 31, 2023, a +53.87% rise year-over-year.
ANI Pharmaceuticals Inc (ANIP) Net Income 2024
ANIP net income (TTM) was $18.78 million for the quarter ending December 31, 2023, a +139.21% increase year-over-year.
ANI Pharmaceuticals Inc (ANIP) Cash Flow 2024
ANIP recorded a free cash flow (TTM) of $100.45 million for the quarter ending December 31, 2023, a +310.77% increase year-over-year.
ANI Pharmaceuticals Inc (ANIP) Earnings per Share 2024
ANIP earnings per share (TTM) was $0.82 for the quarter ending December 31, 2023, a +126.97% growth year-over-year.
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Cap:
|
Volume (24h):